Expertise in
8
conditions

Silvia Betti

Rome, IT 
Expertise in
8
conditions
Rome, IT 

Overview

Silvia Betti practices practicing medicine in Rome, Italy.

Ms. Betti is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Mesenteric Venous Thrombosis, Essential Thrombocythemia, and Polycythemia Vera.

She is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Rome, Italy
Other Locations
Milan, 20133, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Other
View 3 Less Clinical Trials

50 Total Publications

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.
Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.
Journal: Blood advances
Published: May 18, 2026

Frequently Asked Questions about Silvia Betti

Is Silvia Betti a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Silvia Betti is classified as an Elite expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Silvia Betti participate in research or clinical trials?

Yes. Silvia Betti has published 50 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Silvia Betti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Betti's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile